Recent advances in pulmonary hypertension therapy

Area of Science:

• Anesthesiology
• Cardiovascular Pharmacology
• Pulmonary Hypertension Management

Background:

• Cardiovascular anesthesiologists traditionally use intravenous therapy to manage hemodynamics during cardiac surgery.
• General anesthesia combines intravenous and inhaled therapies for analgesia, amnesia, muscle relaxation, and autonomic blockade.
• Inhaled drug delivery, while expertly managed by anesthesiologists, faces challenges in timing, dosage accuracy, and consistency.

Purpose of the Study:

• To review recent advances in inhaled therapy for pulmonary hypertension and right ventricular failure in the perioperative setting.
• To discuss the pharmacology of inhaled drugs targeting the pulmonary endothelium for acute reactive pulmonary vasculature.
• To examine recent patents related to inhaled treatments for cardiovascular conditions.

Main Methods:

• Review of current literature on inhaled pharmacology for perioperative cardiovascular conditions.
• Focus on advances in inhaled drug therapy for pulmonary hypertension and ventricular failure.
• Inclusion of recent patents concerning inhaled treatments.

Main Results:

• Inhaled therapies offer a rapid method for treating acute reactive pulmonary vasculature.
• Pulmonary hypertension and right ventricular failure are significant predictors of morbidity and mortality in cardiac surgery.
• Advances in inhaled drug pharmacology are crucial for managing these perioperative challenges.

Conclusions:

• Inhaled therapies represent a critical advancement in managing perioperative pulmonary hypertension and right ventricular failure.
• Directly acting on the pulmonary endothelium via inhaled drugs is a promising strategy.
• Continued research and development in inhaled pharmacology are essential for improving patient outcomes in cardiac surgery.